Shares in Inovio Pharmaceuticals (NSDQ:INO) have fallen today after the biotech company missed expectations on Wall Street with its first quarter earnings results. The Plymouth Meeting, Penn.-based company posted losses of $32.4 million, or 36¢ per share, on sales of $1.5 million for the three months ended March 31, seeing losses grow 40.1% while sales shrunk […]
Inovio Pharmaceuticals
Inovio snags $56m award for Lassa fever, MERS vaccines
Inovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome. According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and […]
Inovio Pharmaceuticals logs Q4 earnings, sales beat
Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss of -$21.5 million on sales of $8.8 million for the 3 months ended Dec. 31, for bottom-line growth of 17.9% on sales growth of 3.5% compared with […]
Inovio lands $23m in collab with ApolloBio for HPV immunotherapy
Inovio Pharmaceuticals (NSDQ:INO) has inked an amended collaboration and licensing deal with ApolloBio for its DNA immunotherapy product designed to treat the pre-cancers caused by human papillomavirus. The exclusive partnership is limited to China, Hong Kong, Macao and Taiwan, but it could also include the Republic of Korea over the next three years, Inovio reported. In […]
Inovio touts first-in-man Ph1 trial of Zika virus vaccine
Inovio Pharmaceuticals (NSDQ:INO) touted today positive safety and immune response data from the first-in-man Phase I trial of its vaccine against the Zika virus. The trial showed that Inovio’s DNA-based vaccine triggered high levels of binding antibodies in all 40 participants. The team also reported observing a strong neutralizing antibody and T-cell immune response in vaccinated […]
Inovio tops Q2 sales estimate by $4m
Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company posted a net loss of -$9.5 million on sales of $20.4 million for the 3 months ended June 30, for bottom-line growth of 49% compared with the same period last year. Get the full […]
Inovio prices $75m public offering
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced its underwritten public offering of 12.5 million shares of common stock at $6.00 apiece. The offering is expected to bring in nearly $75 million for the Plymouth Meeting, Penn.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy up […]
Inovio looks to raise $75m in public offering
Inovio Pharmaceuticals (NSDQ:INO) said yesterday that it is launching an underwritten public offering to sell $75 million shares of common stock. The Plymouth Meeting, Penn.-based company said it plans to grant underwriters an option to buy up to $11.3 million additional shares of common stock. Get the full story at our sister site, Drug Delivery Business News.
Inovio launches late-stage cervical dysplasia trial after FDA lifts hold
Shares in Inovio Pharmaceuticals (NSDQ:INO) jumped more than 10% after it announced that it is launching a Phase III clinical study of its investigational DNA immunotherapy candidate designed to treat cervical dysplasia caused by human papillomavirus. The moves comes after the FDA lifted a hold that it placed on the clinical program in October last year. At […]
FDA delays Inovio phase III trial of DNA immunotherapy candidate
Inovio Pharmaceuticals (NSDQ:INO) said today that the FDA placed a hold on its proposed Phase III clinical program for its investigational DNA immunotherapy candidate designed to treat pre-cancers and cancers caused by human papillomavirus. The California-based company completed a randomized, double-blind Phase II trial of the candidate in July 2014, evaluating the DNA immunotherapy treatment in women […]
Inovio Pharma picks up Bioject
Inovio Pharmaceuticals said today it paid $5.5 million for the assets of Bioject Medical Technologies including its needle-free jet injection tech, devices and intellectual property With the acquisition, Inovio said it will advance an integrated non-invasive delivery device combining the acquired jet injection tech with its own needle-free skin-surface electroporation tech. Inovio said it’s goal […]